Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa

Zanidatamab is a humanized bispecific IgG1 monoclonal antibody targeting two non-overlapping epitopes of HER2 (ECD2 and ECD4), with immunomodulating and antineoplastic activities. It has shown anti-tumor activity across various solid tumors with HER2 expression or amplification. M.W 148.28 kDa

Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa

Tebotelimab is a humanized bispecific DART molecule targeting PD-1 and LAG-3, with immunomodulatory and antineoplastic activities. It enhances T-cell activation by blocking both checkpoints and has shown anti-tumor activity, including in combination with anti-HER2 therapies. M.W 165.68 kDa

APV-527 is a bispecific antibody targeting 4-1BB on T-cells and the 5T4 tumor antigen to stimulate immune responses against solid tumors. It is being developed for advanced solid tumors, including non-small cell lung cancer, breast cancer, and pancreatic cancer, with positive safety and efficay. M.W 157.94 kDa

Navicixizumab is a bispecific monoclonal antibody targeting DLL4 and VEGF, with potential anti-angiogenic and antineoplastic activities. It has shown antitumor effects in multiple cancer types, with the most promising results in ovarian cancer. M.W 146.17 kDa

Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa

Faricimab is a humanized bispecific antibody that targets vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), key regulators of vascular leakage and inflammation. It is used to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion, improving retinal vascular stability. M.W 146.41 kDa

Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa

Reozalimab(Ibi318) is a first-in-class recombinant IgG1 bispecific antibody that targets both PD-1 and PD-L1, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It fully blocks the PD-1 pathway, disrupts PD-L1/CD80 interactions, and enhances T cell activation for improved tumor cell killing. M.W 143.84 kDa